Uni Bio Science: Opens Hong Kong Research Center, the focus of Future R&D in four major businesses

Immediate Release

June 13, 2022

(Stock Code: 00690.HK)

Uni-Bio Science Group has opened a research center in Hong Kong

Future R&D focus on four major businesses

[13 June 2022 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Company” with its subsidiaries, “Group”; Stock Code: 00690.HK) is pleased to announce the launch of its new research center in Hong Kong. focused on stem cell exosomes, synthetic biology, nanomaterials, and protein engineering. Leveraging the mature scientific ecosystem of Hong Kong Science Park, the new laboratory can quickly and efficiently develop new innovative bioproducts, expanding the Group’s product line, redesigning its R&D system and opening a new strategic growth space.

The four major business “punch combinations”

Official operations of Hong Kong’s new R&D platform The Group’s business model has been upgraded to a “four-wheel drive” model, mainly including high-value generics, bio-innovative medicines, new skin care raw materials and CMOs. focusing on diabetes, ophthalmology, orthopedics and other therapeutic areas. The new R&D model provides the Group with a diversified asset base, as well as the creation of new “S-curve” opportunities for growth in the near future.

First, high-value generic drugs are one of the most important “ammunition” for pharmaceutical companies in the context of reducing the burden of medical insurance. The group’s product, BOSHUTAI® (Acarbose Tablets), was successfully selected by the Henan Thirt Provinces Alliance at a reasonable price for centralized purchasing on the 2nd.nd This June

康 生物 科技 集团 Uni-Bio Science Group Limited


Unit 502, 5 / F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong 新界 沙田 香港 科学 园 科技 大道 东 205502

Tel .: +852 3102 3232 Email: [email protected] Website: www.uni-bioscience.com

in. Last year, the Group’s PINUP® anti-fungal drug (Voriconazole Tablets) also stood out from the competition, ranking first in the procurement volume. In the future, these two products will continue to gain market share and contribute to a stable source of income. It is noteworthy that the Group has recently begun to develop single-use diquafosol eye drops (without preservatives), indicated for dry eye syndrome, through a strategic partnership with API manufacturers. The proposed single-use form uses the state-of-the-art BFS manufacturing technology deployed by the Group, which is safer and more convenient compared to traditional multi-dose drops.

Second, innovative biologic medications are the “source” of the company’s vitality. The successful product of the developing Group, Uni-PTH, is expected to present a new application for the marketing of medicines this year. The clinical work of the Uni-GLP-1 injection pen is also accelerating, and the development of oral dosage forms is also being prepared. In addition, sales of GeneTime® and GeneSoft® core products were fully recovered from the pandemic. Product resilience represents the advantage of product competitiveness at such a challenging time. Therefore, the Group is duplicating the product by examining innovative formulations of EGF, such as BFS dosage and nanofiber forms, to further extend the life cycle of the product, expand its scope and continue to release value. In terms of cutting-edge innovation, the Group is also looking at new drug candidates using new antibodies modalitiescollaboration in the development of single-domain antibodies for use in AMD and other retinal diseases.

In terms of new skin care raw materials, the Group is a leader in product innovation with material innovation. Especially as effective skin care is becoming more and more popular, synthetic biology is becoming a key direction for research with disruptive potential in space. The new skin care ingredients being researched in the group’s new lab include collagen, fibronectin, beauty peptides, probiotics and exosomes. The materials are safe in composition, excellent in efficiency and widely used. The team will take full advantage of HKSTP’s research ecosystem, as well as Uni-Bio’s bioprocessing platform, to market these 5 products quickly. The earliest products can reach the market as early as 1H 2023.

Finally, leveraging the Group’s strong business knowledge of marketing and bio-manufacturing, the Group has launched a pre-filled syringe / lyophilized powder filling line that can be combined with pilot and clinical sample processing. vial injection / freeze-dried powder, cartridge injection and pre-filled injection, and has attracted strategic cooperation with many customers in recent years. Given the success of the CMO business, the Group intends to invest more in expanding it

康 生物 科技 集团 Uni-Bio Science Group Limited


Unit 502, 5 / F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong 新界 沙田 香港 科学 园 科技 大道 东 205502

Tel .: +852 3102 3232 Email: [email protected]science.com Website: www.uni-bioscience.com

CMO’s ability to cover a wider range of potential customers, as well as to integrate new manufacturing technologies to provide a different solution compared to other market participants.

Innovation empowerment, hard work and strategic plan

As an excellent company that integrates R&D, production and sales in the field of biological peptides, the Group attaches great importance to R&D innovation and builds a “small but beautiful” R&D platform that integrates production, education and research well. The dedication to innovation can be demonstrated in 2021, where the Group’s R&D expenditure increased by 23.3% year-on-year to HK $ 50.2 million due to the COVID-19 pandemic. This year too, the Group is actively expanding its research and development cooperation avenues, multilevel research and development cooperation with the University of Hong Kong China, NAMI, etc., and shares technological achievements to further enhance the company’s comprehensive research and development. strength.

However, the success or creation of a strong company in the field of biomedicine is not achieved overnight, and there is no “easy solution”. It requires long-term investment, repeated experiments, and ongoing research and development. “Innovation is the driving force behind the development of pharmaceutical companies. To do this, we need to deepen our innovation and pave the way for innovation. Over the last five years, 20% of our revenue has been invested in innovation and research and development. What we want to do is benefit more patients and improve the quality and value of medicines, ”said Dr. Li, the team’s head of research and development.

In the future, the Group will adhere to its “strong R&D” path, constantly working on its internal strength. In the short term, existing product lines will continue to provide stable revenues to the Group. In the medium term, the continuous repetition of epidermal growth factor products will promote the EGF franchise and the main brand for the expansion of dosage forms and application scenarios. In the long run, we are committed to cutting-edge products in medicine and aesthetics, diabetes and other endocrine fields. The group is particularly excited about the prospects for its oral GLP-1 and non-injection single-domain antibody programs.

康 生物 科技 集团 Uni-Bio Science Group Limited


Unit 502, 5 / F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong 新界 沙田 香港 科学 园 科技 大道 东 205502

Tel .: +852 3102 3232 Email: [email protected] Website: www.uni-bioscience.com


About the Uni-Bio Science Group

Uni-Bio Science Group Limited is primarily engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a comprehensive genetic engineering product development system with a pilot plant test that meets NMPA requirements. The group has two GMP manufacturing bases in Beijing and Shenzhen. The group also has an effective marketing platform and marketing network. The group focuses on the development of innovative treatments and innovative medicines in therapeutic areas of endocrine, such as diabetes and osteoporosis, ophthalmology and dermatology. Please visit Uni-Bio Science Group’s official website for more information: www.uni-bioscience.com/

For more information, contact:

Email: [email protected]

康 生物 科技 集团 Uni-Bio Science Group Limited


Unit 502, 5 / F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong 新界 沙田 香港 科学 园 科技 大道 东 205502

Tel .: +852 3102 3232 Email: [email protected] Website: www.uni-bioscience.com


Uni-Bio Science Group Ltd. published this content June 13, 2022 and is solely responsible for the information contained therein. Distributed to the public, unedited and unmodified June 13, 2022 10:52:08 UTC.

Publicnow 2022


Sales 2021 353 M
45.0 M
45.0 M
2021 net profit -19.6 M
-2.50 m
-2.50 m
Net Cash 2021 84.7 M
10.8 M
10.8 M
P / E ratio 2021 -27.1x
2021 yield
Capitalization 395 M
50.3 M
50.3 M
EV / Sales 2020 3.17x
EV / Sales 2021 1.27x
Number of employees 326
Free-float 44.4%



Uni-Bio Science Group Limited Technical Analysis Diagram |  MarketScreener

Technical analysis trends UNI-BIO SCIENCE GROUP LIMITED

Short term Half term In the long run
Trends Bearish Bearish Bearish

Evolution of Income Accounts


Leave a Comment